A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)-MedSci.cn

A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: preliminary analysis for first-line (1L) treatment of non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and neck (SCCHN)

Riess, JW; Cohen, E; Spicer, J; Shaw, PH; Perez, JR; Rodríguez, LM; Chaney, MF; O'Neill, S; Pedersen, AW; McDowell, D; Ehrnrooth, E; Lopez, PG

ANNALS OF ONCOLOGY, 2023; 34 (): S630

科室
- - 订阅+
  - 更多科室
工具
服务